Roche Holding AG / Santaris Pharma A/S

Multiple (platform deal: oncology, hepatitis C, cardiovascular/dyslipidemia)

Disease Overview

This was a platform acquisition rather than a single-indication deal. Santaris's Locked Nucleic Acid (LNA) chemistry produces shorter, more potent antisense and anti-microRNA oligonucleotides addressable across hepatitis C (miravirsen targeting miR-122), oncology (HIF-1alpha, survivin programs) and cardiovascular dyslipidemia (PCSK9, apoB).

Competitive Landscape

By August 2014 the RNA-targeted therapeutics arena was crowded and capital-intensive. Ionis (then Isis) Pharmaceuticals dominated 2nd-generation antisense, partnered broadly with Biogen, GSK and AstraZeneca; Alnylam led siRNA with Sanofi-Genzyme alignment; Arrowhead and Dicerna were early-stage siRNA challengers. Santaris's LNA chemistry differentiated on potency-per-base and tissue distribution, yielding partnerships with Pfizer, GSK, BMS, Shire and Enzon that produced clinical candidates Roche could leverage. Roche had previously exited RNAi in 2010 after the Alnylam licensing wind-down, so the Santaris purchase was a re-entry signal at a time when major pharma was consolidating oligonucleotide platforms. FierceBiotech and Evaluate analysts framed the deal as defensive - Santaris was reportedly preparing an IPO, and Roche moved before the option closed. Strategically, the Copenhagen site was rebranded as the Roche Innovation Center Copenhagen, anchoring oligonucleotide R&D until its 2023 closure when activities transitioned to Novo Nordisk - underscoring that the platform thesis ultimately did not produce a Roche-marketed LNA drug.